• Latest
  • Trending
  • All
cancer drugs

Centre to cap trade margins on cancer drugs, SC calls for broader price review

October 12, 2026
Natco Pharma’s Q2 net profit falls nearly 61 pc to Rs 203 crore

Natco Pharma’s Q2 net profit falls nearly 61 pc to Rs 203 crore

November 13, 2026
anti-cancer drugs

Centre directs strict vigil to enforce lower prices for 137 anti-cancer drugs

November 13, 2026
WHO report

Tuberculosis deaths decline 38 pc in India since 2015: WHO report

November 13, 2026
Virat Kohli

Virat Kohli gifts Indian jersey to Matt Henry after Kiwi pacer’s carnage leads NZ to win

November 13, 2026
New Zealand thrash India

4th ODI: Henry six-for, Young’s century helps New Zealand thrash India by 244 runs 

November 13, 2026
Deepti Sharma

Deepti Sharma named ICC Women’s Player of the Month for October

November 13, 2026
Scary Picture

Rana Daggubati unveils first asset of Kangana Ranaut’s ‘Scary Picture’

November 13, 2026
Dhindora Season 2

Bhuvan Bam on ‘Dhindora Season 2’: I wanted these characters to be outlandish yet familiar

November 13, 2026
Trump

Trump threatens to double Mexico tariffs

November 13, 2026
Australia

Australia: Woman seriously injured in western Sydney shooting

November 13, 2026
CM Bhagwant Singh Mann

CM Bhagwant Singh Mann Announces Major Gift For More Than 24 Lakh Electricity Consumers In Punjab

November 13, 2026
Speaker Kultar Singh Sandhwan

PUNJAB VIDHAN SABHA SPEAKER KULTAR SINGH SANDHWAN GREETS PEOPLE OF PUNJAB ON THE BIRTH ANNIVERSARY OF SHER-E-PUNJAB MAHARAJA RANJIT SINGH

November 13, 2026
Punjabi News
Hindi News
Friday, November 13, 2026
21 °c
Chandigarh
24 ° Wed
25 ° Thu
25 ° Fri
25 ° Sat
No Result
View All Result
Wishav Warta Times Logo
  • Home
  • News
  • Punjab
  • Haryana
  • Himachal
  • National
  • International
  • Sports
  • Entertainment
  • Health
  • Contact Us
WishavWarta -Web Portal - Punjabi News Agency
No Result
View All Result

Centre to cap trade margins on cancer drugs, SC calls for broader price review

by Wishav Warta English Team
October 12, 2026
in Health
cancer drugs

Centre to cap trade margins on cancer drugs, SC calls for broader price review

New Delhi, Oct 12 (IANS/WISHAVWARTA) The Centre on Monday informed the Supreme Court that it has decided to regulate trade margins on anti-cancer medicines by capping them at 30 per cent of the maximum retail price (MRP), while the apex court called for a broader review of medicine pricing across the pharmaceutical sector.

Solicitor General Tushar Mehta, appearing for the Union government, told a bench of Justices Vikram Nath and Sandeep Mehta that the Centre would notify a list of cancer drugs to which the trade margin cap would apply.

The Centre’s second highest law officer submitted that the list could be periodically updated to include additional anti-cancer medicines, depending on market developments and public health considerations, while excluding inexpensive drugs.

The development came after the apex court repeatedly questioned the substantial disparity between the price at which medicines are supplied to retailers and the MRP printed on them, raising concerns over the financial burden on patients and the need for an effective regulatory framework.

However, the Justice Vikram Nath-led Bench questioned whether the proposed measure would address the wider problem of excessive trade margins on medicines and medical devices beyond the anti-cancer segment.

During the hearing, the top court cited the example of an Indian-made cardiac stent supplied to retailers at around Rs 5,000 but carrying an MRP of Rs 25,000, and questioned the justification for such a disparity.

SG Mehta responded that stents were already subject to price caps.

The bench also referred to the pricing of another drug, citing an MRP of Rs 2,850 against a price to stockist (PTS) of Rs 78.29, and asked the Centre to explain how such pricing arrangements benefited patients.

Additional Solicitor General Aishwarya Bhati submitted that pricing was only one aspect of the government’s policy and that a balance had to be maintained between affordability, availability and market considerations.

“We don’t want to control the entire ecosystem of drugs,” the Centre’s law officer said, arguing that excessive government intervention could adversely affect the market and the availability of medicines.

However, the Supreme Court questioned why the government could not regulate the entire range of medicines and asked the Centre to explain how the existing pricing framework served patients’ interests. It also referred to the Drugs (Prices Control) Order, 2013, and questioned whether medicines subject to price controls reached consumers despite the prescribed trade margins.

The apex court has now posted the matter for further hearing on October 27.

The proceedings arise from public interest litigations (PILs) seeking regulation of medicine prices, initial price fixation of non-scheduled medicines, medical devices, generic medicines and prescription practices.

In earlier hearings, the Supreme Court had questioned why manufacturers were permitted to fix substantially higher MRPs for medicines than the prices at which they supplied them to retailers.

On September 22, the Justice Vikram Nath-led Bench had described the ten-fold difference between the retailer procurement price of an essential cancer medicine and its MRP as “broad daylight dacoity”.

On September 29, the Supreme Court had questioned why a uniform trade margin cap could not be prescribed for pharmaceutical products and flagged concerns over the practice of corporate hospitals requiring patients to purchase medicines from their in-house pharmacies.

The latest proceedings come days after the Supreme Court, in separate proceedings, directed the Centre to constitute a committee to examine the need for statutory regulation of pharmaceutical companies’ marketing practices, including the offering of gifts, hospitality and other benefits to doctors to promote their products. The proposed committee is to consider stakeholder suggestions and objections and recommend whether a statutory framework is required to regulate pharmaceutical marketing practices.

Tags: cancer drugsLatest Punjab NewsPunjab NewsWishavwartatimes.com
Share197Tweet123SendSendShareScan

Related

Natco Pharma’s Q2 net profit falls nearly 61 pc to Rs 203 crore

Natco Pharma’s Q2 net profit falls nearly 61 pc to Rs 203 crore

by Wishav Warta English Team
November 13, 2026
0

Natco Pharma's Q2 net profit falls nearly 61 pc to Rs 203 crore Mumbai, Nov 13 (IANS/WISHAVWARTA) Natco Pharma Limited...

anti-cancer drugs

Centre directs strict vigil to enforce lower prices for 137 anti-cancer drugs

by Wishav Warta English Team
November 13, 2026
0

Centre directs strict vigil to enforce lower prices for 137 anti-cancer drugs New Delhi, Nov 13 (IANS/WISHAVWARTA) The National Pharmaceutical...

WHO report

Tuberculosis deaths decline 38 pc in India since 2015: WHO report

by Wishav Warta English Team
November 13, 2026
0

Tuberculosis deaths decline 38 pc in India since 2015: WHO report New Delhi, Nov 13 (IANS/WISHAVWARTA) India has cut tuberculosis-related...

doctors' safety

IMA Kerala’s new chief puts doctors’ safety, small hospitals on priority list

by Wishav Warta English Team
November 9, 2026
0

IMA Kerala's new chief puts doctors' safety, small hospitals on priority list Thiruvananthapuram, Nov 9 (IANS/WISHAVWARTA) Doctors' safety, welfare, and...

No Content Available

Currency Converter


Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024

Founder ,Editor - DivinderJeet Singh Darshi

Mobile – 97799-23274

Email : DivinderJeet@wishavwarta.in

Recent

Natco Pharma’s Q2 net profit falls nearly 61 pc to Rs 203 crore

Natco Pharma’s Q2 net profit falls nearly 61 pc to Rs 203 crore

by Wishav Warta English Team
November 13, 2026
0

Natco Pharma's Q2 net profit falls nearly 61 pc to Rs 203 crore Mumbai, Nov 13 (IANS/WISHAVWARTA) Natco Pharma Limited...

Most Popular

BREAKING NEWS: PUNJAB POLICE’S STF RAIDS PROPERTIES LINKED TO DRUG INSPECTOR SHISHAN MITTAL; FREEZES 24 BANK ACCOUNTS WITH AMOUNT REACHING ₹6.69Cr

BREAKING NEWS: PUNJAB POLICE’S STF RAIDS PROPERTIES LINKED TO DRUG INSPECTOR SHISHAN MITTAL; FREEZES 24 BANK ACCOUNTS WITH AMOUNT REACHING ₹6.69Cr

by Wishav Warta English Team
August 8, 2024
0

BREAKING NEWS: PUNJAB POLICE’S STF RAIDS PROPERTIES LINKED TO DRUG INSPECTOR SHISHAN MITTAL; FREEZES 24 BANK ACCOUNTS WITH AMOUNT REACHING...

  • About Us
  • Advertise
  • Privacy & Policy
  • Contact Us

COPYRIGHT (C) 2026. ALL RIGHTS RESERVED. DESIGNED AND MAINTAINED BY MEHRA MEDIA 

No Result
View All Result
  • Home
  • News
  • Punjab
  • Haryana
  • Himachal
  • National
  • International
  • Sports
  • Entertainment
  • Health
  • Contact Us

COPYRIGHT (C) 2026. ALL RIGHTS RESERVED. DESIGNED AND MAINTAINED BY MEHRA MEDIA